Pipeline

We focus on high unmet need areas in cardio-metabolic disorders including diabetes and obesity

Asset MOA/Target Indication Discovery Pre Clinical Phase I Phase II Phase III
RT-1000
(Small Molecule)
GLP-1R agonist DM-2 / Obesity

Discovery

Pre-clinical

Phase I

Phase II

Phase III

RT-2000
(Small Molecule)
GIPR agonist DM-2 / Obesity

Discovery

Pre-clinical

Phase I

Phase II

Phase III

RT-3000
(Small Molecule)
GIPR antagonist Obesity

Discovery

Pre-clinical

Phase I

Phase II

Phase III

RT-4000
(Small Molecule)
GLP-1R agonist / GIPR agonist DM-2 / Obesity

Discovery

Pre-clinical

Phase I

Phase II

Phase III

RT-5000
(Small Molecule)
GLP-1R agonist / GIPR antagonist Obesity

Discovery

Pre-clinical

Phase I

Phase II

Phase III

RT-6000
(Small Molecule)
Apelin agonist DM-2 / Obesity

Discovery

Pre-clinical

Phase I

Phase II

Phase III

RT-7000
(Small Molecule)
GLP-1 agonist / Apelin agonist DM-2 / Obesity

Discovery

Pre-clinical

Phase I

Phase II

Phase III